|
|
| Advancing High Potency Manufacturing | Article | Recipharm | Advance potent drug manufacturing through tighter containment, thoughtful process engineering, and closed handling that protects workers while improving efficiency and scale. |
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Gigantic investment manager BlackRock recently gathered powerful investors to discuss along with government officials the nation’s physical and economic backbone. The conversation targeting infrastructure was expansive, but from our vantage point, incomplete. During the 2026 BlackRock Infrastructure Summit discussion of biopharma needs was conspicuous by its absence. How can that be? What industry is more important and more reliant on infrastructure of all kinds? Analysis from Chief Editor Louis Garguilo. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
| Overcoming API Constraints And Tight Timelines | Case Study | Catalent | Use innovative lipid-based formulations and on-demand manufacturing to accelerate Phase 1 trials, enable flexible dose escalation, and maximize limited API for poorly soluble compounds. |
|
|
| How Our Drug Development Model Enhances eNPV | White Paper | Thermo Fisher Scientific | See how an integrated CDMO and CRO model can accelerate development timelines, add up to $62.9 million in value, and help you maximize long-term pipeline success with a single partner. |
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
